Piper Jaffray Companies set a $4.00 price target on Antares Pharma, Inc. (NASDAQ:ATRS) in a research report sent to investors on Wednesday. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

A number of other brokerages also recently issued reports on ATRS. Vetr downgraded Antares Pharma from a buy rating to a hold rating and set a $3.42 price target for the company. in a report on Wednesday, July 12th. HC Wainwright reissued a buy rating and issued a $5.00 price target on shares of Antares Pharma in a report on Friday, June 23rd. Chardan Capital began coverage on Antares Pharma in a report on Friday, June 23rd. They issued a buy rating and a $5.00 price target for the company. Finally, Raymond James Financial, Inc. began coverage on Antares Pharma in a report on Thursday, April 20th. They issued a strong-buy rating and a $4.30 price target for the company. One analyst has rated the stock with a hold rating, three have assigned a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $3.83.

Shares of Antares Pharma (NASDAQ ATRS) opened at 3.13 on Wednesday. The company has a 50-day moving average of $3.10 and a 200 day moving average of $2.71. The stock’s market capitalization is $488.05 million. Antares Pharma has a 12-month low of $1.00 and a 12-month high of $3.37.

Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.01. Antares Pharma had a negative return on equity of 45.05% and a negative net margin of 41.26%. The company had revenue of $12.01 million during the quarter, compared to the consensus estimate of $12.10 million. Analysts predict that Antares Pharma will post ($0.13) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Piper Jaffray Companies Reiterates $4.00 Price Target for Antares Pharma, Inc. (NASDAQ:ATRS)” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.watchlistnews.com/piper-jaffray-companies-reiterates-4-00-price-target-for-antares-pharma-inc-nasdaqatrs/1462185.html.

In related news, insider Fred M. Powell purchased 130,000 shares of the firm’s stock in a transaction on Friday, June 9th. The stock was bought at an average cost of $2.79 per share, with a total value of $362,700.00. Following the completion of the acquisition, the insider now owns 331,434 shares of the company’s stock, valued at approximately $924,700.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 11.60% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Credit Suisse AG acquired a new position in shares of Antares Pharma during the first quarter valued at $146,000. KCG Holdings Inc. increased its position in shares of Antares Pharma by 48.8% in the first quarter. KCG Holdings Inc. now owns 66,717 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 21,881 shares during the last quarter. Thompson Davis & CO. Inc. increased its position in shares of Antares Pharma by 80.8% in the first quarter. Thompson Davis & CO. Inc. now owns 68,386 shares of the specialty pharmaceutical company’s stock valued at $194,000 after buying an additional 30,560 shares during the last quarter. M&T Bank Corp acquired a new position in shares of Antares Pharma during the first quarter valued at $227,000. Finally, Citadel Advisors LLC increased its position in shares of Antares Pharma by 350.5% in the first quarter. Citadel Advisors LLC now owns 83,882 shares of the specialty pharmaceutical company’s stock valued at $238,000 after buying an additional 65,262 shares during the last quarter. 32.07% of the stock is owned by institutional investors and hedge funds.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.